Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Apply
Taletrectinib
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step